Significance: Epigenetics involves alterations in gene expression without changing the nucleotide sequence. Because some epigenetic changes can be reversed chemically, epigenetics has tremendous implications for disease intervention and treatment. Recent Advances: After epigenetic components in cancer were characterized, genes and pathways are being characterized in other diseases such as diabetes, obesity, and neurological disorders. Observational, experimental, and clinical studies in different diseases have shown that nutrients influence epigenetic regulation. Nutrients such as folic acid that supply methyl groups have been shown to have a protective effect in colon cancer. Critical Issues: Identifying steps during epigenetic regulation and developing intervention and treatment agents are the critical issues in the field. Future Directions: Following completion and validation of key observational studies in nutritional epigenetics, strategies can be developed for cancer control and treatment. Antioxid. Redox Signal. 17, 355–364.
Get full access to this article
View all access options for this article.
References
1.
AndersonCM, LopezF, ZimmerA, BenoitJN. Placental insufficiency leads to developmental hypertension and mesenteric artery dysfunction in two generations of Sprague-Dawley rat offspring. Biol Reprod, 74:538–544. 2006.
BeumerJH, TawbiH. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr Clin Pharmacol, 5:196–208. 2010.
4.
BommareddyA, ArasadaBL, MatheesDP, DwivediC. Chemopreventive effects of dietary flaxseed on colon tumor development. Nutr Cancer, 54:216–222. 2006.
5.
BryzgunovaOE, MorozkinES, YarmoschukSV, VlassovVV, LaktionovPP. Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann N Y Acad Sci, 1137:222–225. 2008.
6.
CarrDF, WhiteleyG, AlfirevicA, PirmohamedM. FolATED study team. Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review. Pharmacogenomics J, 9:291–305. 2009.
7.
ChangCM, YuCC, LuHT, ChouYF, HuangRF. Folate deprivation promotes mitochondrial oxidative decay: DNA large deletions, cytochrome c oxidase dysfunction, membrane depolarization and superoxide overproduction in rat liver. Br J Nutr, 97:855–863. 2007.
8.
ChenY, GelfondJA, McManusLM, ShiremanPK. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC Genomics, 10:407. 2009.
9.
ChobanianAV. Improved hypertension control: cause for some celebration. JAMA, 303:2082–2083. 2010.
10.
ChobanianAV, BakrisGL, BlackHR, CushmanWC, GreenLA, IzzoJL, JonesDW, MatersonBJ, OparilS, WrightJTJr., RoccellaEJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute; and National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206–1252. 2003.
11.
ChouYF, HuangRF. Mitochondrial DNA deletions of blood lymphocytes as genetic markers of low folate-related mitochondrial genotoxicity in peripheral tissues. Eur J Nutr, 48:429–436. 2009.
12.
CoppedèF. The complex relationship between folate/homocysteine metabolism and risk of Down syndrome. Mutat Res, 682:54–70. 2009.
13.
DammannRH, KirschS, SchagdarsurenginU, DansranjavinT, GradhandE, SchmittWD, HauptmannS. Frequent aberrant methylation of the imprinted IGF2/H19 locus and LINE1 hypomethylation in ovarian carcinoma. Int J Oncol, 36:171–179. 2010.
14.
DavisCD, RossSA. Dietary components impact histone modifications and cancer risk. Nutr Rev, 65:88–94. 2007.
15.
DavisCD, UthusEO, FinleyJW. Dietary selenium and arsenic affect DNA methylation in vitro in Caco-2 cells and in vivo in rat liver and colon. J Nutr, 130:2903–2909. 2000.
16.
DimriM, BommiPV, SahasrabuddheAA, KhandekarJD, DimriGP. Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis, 31:489–495. 2010.
17.
DonkenaKV, YuanH, YoungCY. Vitamin Bs, one carbon metabolism and prostate cancer. Mini Rev Med Chem, 10:1385–1392. 2010.
18.
DuthieSJ. Folate and cancer: how DNA damage, repair and methylation impact on colon carcinogenesis. J Inherit Metab Dis, 34:101–109. 2011.
19.
ElsheikhSE, GreenAR, RakhaEA, PoweD G, AhmedRA, CollinsHM, SoriaD, GaribaldiJM, PaishCE, AmmarAA, GraingeMJ, BallGR, AbdelghanyMK, Martinez-PomaresL, HeeryDM, EllisIO. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res, 69:3802–3809. 2009.
20.
EstellerM. Epigenetics in cancer. N Engl J Med, 358:1148–1159. 2008.
21.
FeinbergAP. Genome-scale approaches to the epigenetics of common human disease. Virchows Arch, 456:13–21. 2010.
22.
FragaMF, BallestarE, Villar-GareaA, Boix-ChornetM, EspadaJ, SchottaG, BonaldiT, HaydonC, RoperoS, PetrieK, IyerNG, Pérez-RosadoA, CalvoE, LopezJA, CanoA, CalasanzMJ, ColomerD, PirisMA, AhnN, ImhofA, CaldasC, JenuweinT, EstellerM. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet, 37:391–400. 2005.
23.
FragaMF, EstellerM. Epigenetics and aging: the targets and the marks. Trends Genet, 23:413–418. 2007.
24.
GanesanA, NolanL, CrabbSJ, PackhamG. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets, 9:963–981. 2009.
25.
GarzonR, CalinGA, CroceCM. MicroRNAs in cancer. Annu Rev Med, 60:167–179. 2009.
26.
GieniRS, HendzelMJ. Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer. Biochem Cell Biol, 87:711–746. 2009.
27.
HanCT, SchoeneNW, LeiKY. Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells. Am J Physiol Cell Physiol, 297:C1188–C1199. 2009.
28.
HeijmansBT, TobiEW, LumeyLH, SlagboomPE. The epigenome: archive of the prenatal environment. Epigenetics, 4:526–531. 2009.
29.
HeijmansBT, TobiEW, SteinAD, PutterH, BlauwGJ, SusserES, SlagboomPE, LumeyLH. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A, 105:17046–17049. 2008.
30.
HongSK, KimJH, LinMF, ParkJI. The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res, 317:2671–2682. 2011.
31.
JelinicP, ShawP. Loss of imprinting and cancer. J Pathol, 211:261–268. 2007.
32.
JohnsonIT, BelshawNJ. Environment, diet and CpG island methylation: epigenetic signals in gastrointestinal neoplasia. Food Chem Toxicol, 46:1346–1359. 2008.
33.
JonesA, WangH. Polycomb repressive complex 2 in embryonic stem cells: an overview. Protein Cell, 1:1056–1062. 2010.
34.
KeijerJ, Bekkenkamp-GrovensteinM, VenemaD, DommelsYE. Bioactive food components, cancer cell growth limitation and reversal of glycolytic metabolism. Biochim Biophys Acta, 1807:697–706. 2011.
35.
KimKC, FrisoS, ChoiSW. DNA methylation, an epigenetic mechanism connecting folate to healthy embryonic development and aging. J Nutr Biochem, 20:917–926. 2009.
36.
KimYS, MilnerJA. Bioactive food components and cancer specific metabolomic profiles. J Biomed Biotech, 2011PMID21113295(In press).
KuG, McManusMT. Behind the scenes of a small RNA gene-silencing pathway. Hum Gene Ther, 19:17–26. 2008.
39.
KulkarniA, Chavan-GautamP, MehendaleS, YadavH, JoshiS. Global DNA methylation patterns in placenta and its association with maternal hypertension in pre-eclampsia. DNA Cell Biol, 30:79–84. 2011.
40.
KumarD, VermaM. Methods in cancer epigenetics and epidemiology. Methods Mol Biol, 471:273–288. 2009.
41.
LairdPW. Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet, 11:191–203. 2010.
42.
LaneAA, ChabnerBA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol, 27:5459–5468. 2009.
LinYW, ChenHM, FangJY. Gene silencing by the Polycomb group proteins and associations with cancer. Cancer Invest, 29:187–195. 2011.
48.
LinkA, BalaguerF, GoelA. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol, 80:1771–1792. 2010.
49.
LopatinaNG, VanyushinBF, CroninGM, PoirierLA. Elevated expression and altered pattern of activity of DNA methyltransferase in liver tumors of rats fed methyl-deficient diets. Carcinogenesis, 19:1777–1781. 1998.
50.
LustbergMB, RamaswamyB. Epigenetic targeting in breast cancer: therapeutic impact and future direction. Drug News Perspect, 22:369–381. 2009.
51.
MaX, EzzeldinHH, DiasioRB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs, 69:1911–1934. 2009.
52.
MarikR, AlluM, AnchooriR, StearnsV, UmbrichtCB, KhanS. Potent genistein derivatives as inhibitors of estrogen receptor alpha-positive breast cancer. Cancer Biol Ther, 11:883–892. 2011.
53.
MarsonCM. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer. Anticancer Agents Med Chem, 9:661–692. 2009.
MeeranSM, AhmedA, TollefsbolTO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics, 1:101–116. 2010.
56.
MillisRM. Epigenetics and hypertension. Curr Hypertens Rep, 13:21–28. 2011.
57.
MilnerJA. Nutrition and cancer: essential elements for a roadmap. Cancer Lett, 269:189–198. 2008.
58.
NafeeTM, FarrellWE, CarrollWD, FryerAA, IsmailKM. Epigenetic control of fetal gene expression. BJOG, 115:158–168. 2008.
59.
PitchakarnP, SuzukiS, OgawaK, PompimonW, TakahashiS, AsamotoM, LimtrakulP, ShiraiT. Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. Cancer Lett, 306:142–150. 2011.
60.
PiuntiA, PasiniD. Epigenetic factors in cancer development: polycomb group proteins. Future Oncol, 7:57–75. 2011.
61.
PlagemannA, HarderT, BrunnM, HarderA, RoepkeK, Wittrock-StaarM, ZiskaT, SchellongK, RodekampE, MelchiorK, DudenhausenJW. Hypothalamic proopiomelanocortin promoter methylation becomes altered by early overfeeding: an epigenetic model of obesity and the metabolic syndrome. J Physiol, 587:4963–4976. 2009.
62.
PogribnyIP, RossSA, WiseC, PogribnaM, JonesEA, TryndyakVP, JamesSJ, DraganYP, PoirierLA. Irreversible global DNA hypomethylation as a key step in hepatocarcinogenesis induced by dietary methyl deficiency. Mutat Res, 593:80–87. 2006.
63.
PoirierLA. Methyl group deficiency in hepatocarcinogenesis. Drug Metab Rev, 26:185–199. 1994.
64.
PowolnyAA, BommareddyA, HahmER, NormolleDP, BeumerJH, NelsonJB, SinghSV. Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. J Natl Cancer Inst, 103:571–584. 2011.
65.
RodriguezRM, FragaMF. Aging and cancer: are sirtuins the link?Future Oncol, 6:905–915. 2010.
66.
RossSA. Evidence for the relationship between diet and cancer. Exp Oncol, 32:137–142. 2010.
67.
RossSA, DwyerJ, UmarA, KaganJ, VermaM, Van BemmelDM, DunnBK. Introduction: diet, epigenetic events and cancer prevention. Nutr Rev, 66,Suppl 1:S1–S6. 2008.
68.
StrakovskyRS, ZhouD, PanYX. A low-protein diet during gestation in rats activates the placental mammalian amino acid response pathway and programs the growth capacity of offspring. J Nutr, 140:2116–2120. 2010.
69.
SzulwachKE, LiX, SmrtRD, LiY, LuoY, LinL, SantistevanNJ, LiW, ZhaoX, JinP. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. J Cell Biol, 189:127–141. 2010.
70.
TimpW, LevchenkoA, FeinbergAP. A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction. Cell Cycle, 8:383–390. 2009.
71.
TobiEW, HeijmansBT, KremerD, PutterH, Delemarre-van de WaalHA, FinkenMJ, WitJM, SlagboomPE. DNA methylation of IGF2, GNASAS, INSIGF and LEP and being born small for gestational age. Epigenetics, 6:171–176. 2011.
72.
TobiEW, LumeyLH, TalensRP, KremerD, PutterH, SteinAD, SlagboomPE, HeijmansBT. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. Hum Mol Genet, 18:4046–4053. 2009.
73.
TrakaMH, SpinksCA, DolemanJF, MelchiniA, BallRY, MillsRD, MithenRF. The dietary isothiocyanate sulforaphane modulates gene expression and alternative gene splicing in a PTEN null preclinical murine model of prostate cancer. Mol Cancer, 9:189–194. 2010.
74.
UlrichCM. Folate and cancer prevention—where to next? Counterpoint. Cancer Epidemiol Biomarkers Prev, 17:2226–2230. 2008.
75.
VaqueroA. The conserved role of sirtuins in chromatin regulation. Int J Dev Biol, 53:303–322. 2009.
76.
VermaM. Viral genes and methylation. Ann N Y Acad Sci, 983:170–180. 2003.
77.
VermaM.The human epigenome and cancer. Human Genome Epidemiology, 2ndKhouryM, BedrosianS, GwinnM, HigginsJ, IoannidisJ, LittleJ. New York: Oxford University Press, 2010; 551–578.
78.
VermaM, KumarD. Diagnosing cancer using histone analysis. Cancer Epigenetics. TollefsbolT.New York: CRC Press, 2009; 347–357.
VermaM, SeminaraD, ArenaFJ, JohnC, IwamotoK, HartmullerV. Genetic and epigenetic biomarkers in cancer: improving diagnosis, risk assessment, and disease stratification. Mol Diagn Ther, 10:1–15. 2006.
81.
VillagraA, SotomayorEM, SetoE. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene, 29:157–173. 2010.
82.
VuTH, NguyenAH, HoffmanAR. Loss of IGF2 imprinting is associated with abrogation of long-range intrachromosomal interactions in human cancer cells. Hum Mol Genet, 19:901–919. 2010.
83.
WanSG, TaccioliC, JiangY, ChenH, SmalleyKJ, HuangK, LiuXP, FarberJL, CroceCM, FongLY. Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression. Int J Cancer, 129:331–345. 2011.
84.
WilliamsD, VergheseM, WalkerLT, BoatengJ, ShackelfordL, ChawanCB. Flax seed oil and flax seed meal reduce the formation of aberrant crypt foci (ACF) in azoxymethane-induced colon cancer in Fisher 344 male rats. Food Chem Toxicol, 45:153–159. 2007.
85.
WuMY, KuoCS, LinCY, LuCL, Syu HuangRF. Lymphocytic mitochondrial DNA deletions, biochemical folate status and hepatocellular carcinoma susceptibility in a case- control study. Br J Nutr, 102:715–721. 2009.
86.
YanH, ZhuY, LiuB, WuH, LiY, WuX, ZhouQ, XuK. Mitogen-activated protein kinase mediates the apoptosis of highly metastatic human non-small cell lung cancer cells induced by isothiocyanates. Br J Nutr, 23:1–13. 2011.
87.
ZeiselSH. Nutritional genomics: defining the dietary requirement and effects of choline. J Nutr, 141:531–534. 2011.
88.
ZhangM, LiuX, HolmanCD. Effect of dietary intake of isoflavones on the estrogen and progesterone receptor status of breast cancer. Nutr Cancer, 62:765–773. 2010.
89.
ZhaoR, DeCoteauJF, GeyerCR, GaoM, CuiH, CassonAG. Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues. Carcinogenesis, 30:2117–2122. 2009.
